Image

The US Food and Drug Administration (FDA) has accepted the filing of Boehringer Ingelheim Pharmaceuticals’ new drug application for its nintedanib and has granted priority review designation for treatment of idiopathic pulmonary fibrosis.

An investigational small molecule tyrosine kinase inhibitor, nintedanib is currently being developed by Boehringer Ingelheim.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company’s submission of the new drug application is supported by positive data from two global Phase III studies, INPULSIS-1 and INPULSIS-2, evaluating the safety and efficacy of nintedanib in treatment of idiopathic pulmonary fibrosis.

Boehringer Ingelheim Pharmaceuticals Clinical Development and Medical Affairs senior vice-president Tunde Otulana said: "If approved, nintedanib may offer a treatment option for people in the US who are living with this progressive disease, and have no approved treatment options today.

"If approved, nintedanib may offer a treatment option for people in the US who are living with this progressive disease."

"We look forward to continuing to work closely with the FDA during this review period."

The FDA granted orphan-drug designation for nintedanib in June 2011, and fast-track designation in June 2013.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Nintedanib targets growth factors, which have been shown to be potentially involved in pulmonary fibrosis, the vascular endothelial growth factor receptor, fibroblast growth factor receptor, and platelet-derived growth factor receptor.

According to Boehringer Ingelheim Pharmaceuticals, the safety and efficacy of nintedanib in the treatment of idiopathic pulmonary fibrosis has not been established.

Image: High-resolution computed tomography scans of the chest of a patient with idiopathic pulmonary fibrosis. Photo: courtesy of IPFeditor.